MedXtractor Fills a Key Gap in Mental Health Treatments


Ryan Allway

June 30th, 2021

App, Exclusive, Psychedelics, Top News


 

According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated.

MedXtractor Corp.’s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Let’s take a closer look at the challenges facing mental health treatments and how SHAMAN and psychedelics could play critical roles in improving them.

Mental Health Challenges

Mental health disorders affect a high percentage of the population. For example, mood and anxiety disorders affect nearly one-third of the U.S. population. In addition, a relatively high rate of people experiencing these conditions visit their primary care physician with physical complaints, like fatigue, creating an opportunity for diagnosis and treatment.

Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. For example, research shows that primary care physicians misdiagnosed 65.9% of patients with major depressive disorder, 92.7% of patients with bipolar disorder, 71% of patients with generalized anxiety disorder, and 97.8% of patients with social anxiety disorder.

Even if there’s an accurate diagnosis, many mental health treatments have less-than-desirable efficacy, and there can be significant side effects. Psychedelics could offer a better alternative for many patients. Still, years of prohibition have set back clinical trials, and there’s not a lot of information about how and when to administer these kinds of treatments.

Psychedelics Provide a Solution

Psychedelics have been used for thousands of years in religious ceremonies and as part of various cultures. These days, over 30 million people in the U.S. have used psychedelics for mystical experiences, curiosity, and introspection. The widespread use has made it clear that they don’t cause organ damage, withdrawal symptoms, or elicit compulsive use.

Researchers are just starting to uncover the potential for psychedelics to treat mental health disorders. For example, in a small study of adults with major depression, Johns Hopkins researchers found that two doses of psilocybin with psychotherapy produced rapid and significant reductions in depressive symptoms. Half of the participants were in complete remission through four weeks.

Despite the tremendous promise of psychedelics, there are no large-scale standardized clinical trials or data sources that clinicians can use to guide their patient decisions. Many studies thus far involve only a small number of participants and have a minimal focus without an eye toward mainstream applications at a clinical level.

Building the Data Backend

MedXtractor is leveraging machine learning to predict the impact of psychedelics and psychotropics on mental health disorders through its SHAMAN program. With extensive and ever-expanding validated data, the platform can provide high-resolution opinions on the probabilities related to many mental health afflictions.

Psychedelics and psychotropics and their potential application to mental health afflictions are SHAMAN’s initial target. In mid-June, the company announced that it has collected more than 400 complete reference records and is on track to reach its target of 500 complete reference records by June 30, 2021.

The company hopes to reach its Phase 3 target of 800 reference records by the end of August and launch the platform in December. In the meantime, management is focused on tight cost controls to keep project costs under budget while developing mHeath applications and their bio-extraction business operations.

Looking Ahead

Mental health disorders cost the global economy trillions of dollars each year, but screening, diagnosis, and treatment remain largely ineffective despite their prevalence. Psychedelics could play a role in turning around these trends, but clinicians require more data to properly diagnose patients and determine if psychedelic therapies are suitable for them.

MedXtractor Corp. (CSE: MXT) (OTC: MXTTF) is leveraging machine learning to garner insights from hundreds of complete medical records. Using these insights, the company hopes to provide high-resolution opinions on the probabilities related to many mental health afflictions.

Investors may want to take a closer look at the stock as it continues to collect complete reference records ahead of its launch late this year. For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading